PAPERS

Check Jones Google Scholar page for an up to date list

Peer-reviewed manuscripts:

Malichova F, Swann P, Kigar SL, Savinykh Yarkoni N, Goddard J, Chouliaras L, Surendranathan A, Turner L, Savulich G, Bevan-Jones R, Ashton NJ, Blennow K, Zetterberg H, Needham EJ, Jones JL, McEwan WA, Rowe JB, O’Brien JT, Malpetti M. Blood-based immunophenotyping of T cell profiles in patients with neurodegenerative disorders. Alzheimer’s Research & Therapy. 2026. DOI: 10.1186/s13195-026-02144-y

Georgieva ZG, Howlett SK, Rainbow DB, Coppard V, Ellis L, Jarvis LB, Williams E, Yang JHM, Sun B, Tree T, Coles AJ, Wicker LS, Jones JL. Low-dose IL-2 fails to expand Tregs after alemtuzumab: insight into impaired immune tolerance in multiple sclerosis. Brain. 2026. DOI: 10.1093/brain/awag171

Curle AJ, Fazal SV, Qarin S, Howlett SK, He X, Barker RA, Jones JL. The immunological profile of RC17 hESC-derived dopaminergic neural progenitor cells in vitro: implications for the STEM-PD clinical trial. Stem Cell Reports. 2026. DOI: 10.1016/j.stemcr.2026.102818

Graham R, Davies A, Mullin M, Gear D, Day A, Wei B, Benafif S, Khaw C, Selway-Clarke H, Popova B, Yamada D, Howlett S, Galani S, Szmul A, Riddell A, Nair A, Krebs M, Kalber T, Jacob J, Chowdary P, Jones JL, Sage B, Wheeler G, Kolluri K, Lowdell M, Forster M, Janes S. A first-in-human phase I clinical trial investigating the safety and efficacy of cell therapy MSCTRAIL in patients with advanced lung cancer. Cytotherapy. 2026. DOI: 10.1016/j.jcyt.2026.102101

Mousa R, Invernizzi P, Jones JL, Mousa HS. HTNFSF14 (LIGHT) in intestinal inflammation: balancing immune activation and resolution in IBD. Frontiers in Immunology. 2025. DOI: 10.3389/fimmu.2025.1657071

Wells SB*, Rainbow DB*, Mark M*, Szabo PA*, Ergen C*, Maceiras AR*, Caron DP, Rahmani E, Benuck E, Amiri VVP, Chen D, Wagner A, Howlett SK, Jarvis LB, Ellis KL, Kubota M, Matsumoto R, Mahbubani K, Saeb-Parsy K, Dominguez-Conde C, Richardson L, Xu C, Li S, Mamanova L, Bolt L, Wilk A, Teichmann SA**, Farber DL**, Sims PA**, Jones JL**, Yosef N**. Multimodal profiling reveals tissue-directed signatures of human immune cells altered with age. Nature Immunology. 2025;26:1612–1625. DOI: 10.1038/s41590-025-02241-4
*Co-first authors; **Co-senior and corresponding authors.

Coppard V, Szep G, Georgieva Z, Howlett SK, Jarvis LB, Rainbow DB, Suchanek O, Needham EJ, Mousa HS, Menon DK, Feyertag F, Mahbubani KT, Saeb-Parsy K, Jones JL. FlowAtlas: an interactive tool for high-dimensional immunophenotyping analysis bridging FlowJo with computational tools in Julia. Frontiers in Immunology. 2024;15:1425488. DOI: 10.3389/fimmu.2024.1425488

Gray JI, Caron DP, Wells SB, Guyer R, Szabo P, Rainbow DB, Ergen C, Rybkina K, Bradley MC, Matsumoto R, Pethe K, Kubota M, Teichmann S, Jones J, Yosef N, Atkinson M, Brusko M, Brusko TM, Connors TJ, Sims PA, Farber DL. Human γδ T cells in diverse tissues exhibit site-specific maturation dynamics across the life span. Science Immunology. 2024;9(96):eadn3954. DOI: 10.1126/sciimmunol.adn3954

Balestri W, Sharma R, da Silva VA, Bobotis BC, Curle AJ, Kothakota V, Kalantarnia F, Hangad MV, Hoorfar M, Jones JL, Tremblay M-È, El-Jawhari JJ, Willerth SM, Reinwald Y. Modeling the neuroimmune system in Alzheimer’s and Parkinson’s diseases. Journal of Neuroinflammation. 2024;21:32. DOI: 10.1186/s12974-024-03024-8

Brown JWL, Prados F, Altmann DR, Kanber B, Stutters J, Cunniffe NG, Jones JL, Georgieva ZG, Needham EJ, Daruwalla C, Gandini Wheeler-Kingshott CAM, Connick P, Chandran S, Franklin RJM, MacManus D, Samson R, Coles AJ, Chard DT. Remyelination varies between and within lesions in multiple sclerosis following bexarotene. Annals of Clinical and Translational Neurology. 2022;9:1626–1642. DOI: 10.1002/acn3.51662

Domínguez Conde C*, Xu C*, Jarvis LB*, Rainbow DB*, Wells SB*, Gomes T, Howlett SK, Suchanek O, Polanski K, King HW, Mamanova L, Huang N, Szabo PA, Richardson L, Bolt L, Fasouli ES, Mahbubani KT, Prete M, Tuck L, Richoz N, Tuong ZK, Campos L, Mousa HS, Needham EJ, Pritchard S, Li T, Elmentaite R, Park J, Rahmani E, Chen D, Menon DK, Bayraktar OA, James LK, Meyer KB, Yosef N, Clatworthy MR, Sims PA, Farber DL, Saeb-Parsy K, Jones JL**, Teichmann SA**. Cross-tissue immune cell analysis reveals tissue-specific features in humans. Science. 2022;376(6594):eabl5197. DOI: 10.1126/science.abl5197
*Co-first authors;** Co-senior and corresponding authors.

Coles AJ*, Jones JL*, Vermersch P, Traboulsee A, Bass AD, Boster A, Chan A, Comi G, Fernández Ó, Giovannoni G, Havrdova E, LaGanke C, Montalban X, Oreja-Guevara C, Piehl F, Wiendl H, Ziemssen T. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: benefit/risk following review of trial and post-marketing data. Multiple Sclerosis Journal. 2021. DOI: 10.1177/13524585211061335
*Co-first authors.

Mousa HS, Jones JL. The yin and yang of intracellular reactive oxygen species following T-cell activation. Brain. 2021;144:2909–2911. DOI: 10.1093/brain/awab361

Jarvis LB, Rainbow DB, Coppard V, Howlett SK, Davies JL, Kaur Mullay H, Hester J, Ashmore T, Van Den Bosch A, Grist JT, Coles AJ, Mousa HS, Pluchino S, Mahbubani K, Griffin JL, Saeb-Parsy K, Issa F, Peruzzotti-Jametti L, Wicker LS, Jones JL. Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A-induced expression of CD73. Communications Biology. 2021;4:1–14. DOI: 10.1038/s42003-021-02721-x

Brown JWL, Cunniffe NG, Prados F, Kanber B, Jones JL, Needham E, Georgieva Z, Rog D, Pearson OR, Overell J, MacManus D, Samson RS, Stutters J, ffrench-Constant C, Gandini Wheeler-Kingshott CAM, Michell A, Franklin RJM, Chandran S, Altmann D, Chard DT, Connick P, Coles AJ. A randomised placebo-controlled trial of a retinoid-X receptor agonist’s ability to promote remyelination in people with relapsing-remitting multiple sclerosis. Lancet Neurology. 2021;20:709–720. DOI: 10.1016/S1474-4422(21)00179-4

Digby RJ, Radjabova V, Mousa HS, Menon DK, Coles AJ, Jones JL, Needham EJ. A method to isolate and cryopreserve cerebrospinal fluid mononuclear cells from external ventricular drains to investigate immunological processes in acute brain injuries. Journal of Immunological Methods. 2021;499:113163. DOI: 10.1016/j.jim.2021.113163

Qarin S, Howlett SK, Jones JL, Barker RA. The immunogenicity of midbrain dopaminergic neurons and the implications for neural grafting trials in Parkinson’s disease. Neuronal Signaling. 2021;5(3). DOI: 10.1042/NS20200083

Gaunt C, Rainbow D, Mackenzie R, Jarvis L, Mousa H, Cunniffe N, Georgieva Z, Brown JW, Coles A, Jones JL. The MS remyelinating drug bexarotene (an RXR agonist) promotes induction of human Tregs and suppresses Th17 differentiation in vitro. Frontiers in Immunology. 2021;12:712241. DOI: 10.3389/fimmu.2021.712241

Petrus-Reurer S, Romano M, Howlett S, Jones JL, Lombardi G, Saeb-Parsy K. Immunological considerations and challenges for regenerative cellular therapies. Communications Biology. 2021;4:1–16. DOI: 10.1038/s42003-021-02237-4

Needham EJ, Stoevesandt O, Theilin EP, Zetterberg H, Zanier ER, Al Nimer F, Ashton NJ, Outtrim JG, Newcombe VFJ, Mousa HS, Simren J, Blennow K, Yang Z, Hutchinson PJ, Piehl F, Helmy A, Taussig MJ, Wang KKW, Jones JL, Menon DK, Coles AJ. Complex autoantibody responses occur following moderate to severe traumatic brain injury. Journal of Immunology. 2021. DOI: 10.4049/jimmunol.2001309

Newcombe VF, Spindler LRB, Das T, Winzeck S, Allinson K, Stamatakis EA, Menon DK; Cambridge NeuroCovid Imaging Collaborators. Neuroanatomical substrates of generalized brain dysfunction in COVID-19. Intensive Care Medicine. 2020;47:116–118. DOI: 10.1007/s00134-020-06241-w

Brannigan J, Jones JL, Stacpoole SRL. Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis. Neurology: Neuroimmunology & Neuroinflammation. 2020;7(5):e799. DOI: 10.1212/NXI.0000000000000799

Lechermann LM, Manavaki R, Attili B, Lau D, Jarvis LB, Fryer TD, Bird N, Aloj L, Patel N, Basu B, Cleveland M, Aigbirhio FI, Jones JL, Gallagher FA. Detection limit of 89Zr-labeled T-cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI. EJNMMI Research. 2020;10:1–12. DOI: 10.1186/s13550-020-00667-5

Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, Hayat S, Kuan W, Evans J, Breen D, Cummins G, Jones JL, Clatworthy M, Floto R, Barker RA, Williams-Gray CH. Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson’s disease. Brain, Behavior, and Immunity. 2020;87:473–488. DOI: 10.1016/j.bbi.2020.01.018

Trzupek D, Dunstan M, Cutler A, Lee M, Godfrey L, Jarvis L, Rainbow D, Aschenbrenner D, Jones JL, Uhlig H, Wicker L, Todd J, Ferreira R. Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. Genome Medicine. 2020;12:1–22. DOI: 10.1186/s13073-020-00756-z

Ban M, Liao W, Baker A, Compston A, Thorpe J, Molyneux P, Fraser M, Khadake J, Jones JL, Coles A, Sawcer S. Transcript-specific regulation of expression influences susceptibility to multiple sclerosis. European Journal of Human Genetics. 2020;28:826–834. DOI: 10.1038/s41431-019-0569-0

James KR, Gomes T, Elmentaite R, Kumar N, Gulliver EL, King HW, Stares MD, Bareham BR, Ferdinand JR, Petrova VN, Polanski K, Forster SC, Jarvis LB, Suchanek O, Howlett S, James LK, Jones JL, Meyer KB, Clatworthy MR, Saeb-Parsy K, Lawley TD, Teichmann SA. Distinct microbial and immune niches of the human colon. Nature Immunology. 2020;21:343–353. DOI: 10.1038/s41590-020-0602-z

Brown JWL, Prados Carrasco F, Eshaghi A, Sudre CH, Button T, Pardini M, Samson RS, Ourselin S, Gandini Wheeler-Kingshott CAM, Jones JL, Coles AJ, Chard DT. Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. Multiple Sclerosis Journal. 2020;26:1093–1101. DOI: 10.1177/1352458519852093

Muller I, Moran C, Lecumberri B, Decallonne B, Robertson N, Jones JL, Dayan CM. 2019 European Thyroid Association guidelines on the management of thyroid dysfunction following immune reconstitution therapy. European Thyroid Journal. 2019;8:173–185. DOI: 10.1159/000500881

Coles AJ, Azzopardi L, Kousin-Ezewu O, Mullay HK, Thompson SAJ, Jarvis L, Davies J, Howlett S, Rainbow D, Babar J, Sadler TJ, Brown JWL, Needham E, May K, Georgieva ZG, Handel AE, Maio S, Deadman M, Rota I, Hollander G, Dawson S, Jayne D, Seggewiss-Bernhardt R, Douek DC, Isaacs JD, Jones JL. Keratinocyte growth factor impairs human thymic recovery from lymphopenia. JCI Insight. 2019;4:e125377. DOI: 10.1172/jci.insight.125377

Gao J, Jones JL, Damato EM, Coles A. Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis. Journal of Neurology. 2019;266:1539–1540. DOI: 10.1007/s00415-019-09288-y

Needham EJ, Helmy A, Zanier ER, Jones JL, Coles AJ, Menon DK. The immunological response to traumatic brain injury. Journal of Neuroimmunology. 2019;332:112–125. DOI: 10.1016/j.jneuroim.2019.04.005

Nye CJS, Wagner A, Kousin-Ezewu O, Jones JL, Coles AJ. A case of anaphylaxis to alemtuzumab. Journal of Neurology. 2019;266:780–781. DOI: 10.1007/s00415-019-09214-2

Roos J, Moran C, Chatterjee VK, Jones JL, Coles AJ, Murthy R. Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves’ orbitopathy: a case series. Eye. 2019;33:223–229. DOI: 10.1038/s41433-018-0282-1

Brown JW, Coles AJ, Horakova D, Havrdova E, Prat A, Girard M, Duquette P, Trojano M, Lugaresi A, Bergamaschi R, Grammond P, Alroughani R, Hupperts R, McCombe P, Van Pesch V, Sola P, Ferraro D, Grand’Maison F, Terzi M, Lechner-Scott J, Fletcher S, Slee M, Shaygannejad V, Pucci E, Granella F, Jokubaitis V, Willis M, Rice C, Scholding N, Wilkins A, Person O, Ziemssen T, Hutchinson M, Harding K, Jones JL, McGuigan C, Butzkueven H, Kalincik T*, Robertson NP*. Association of initial disease-modifying therapy with conversion to secondary progressive multiple sclerosis among patients with relapsing-remitting multiple sclerosis. JAMA. 2019;321:175–187. DOI: 10.1001/jama.2018.20588

Willis MD, Hope-Gill B, Flood-Page P, Joseph F, Needham E, Jones JL, Coles A, Robertson NP. Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Multiple Sclerosis Journal. 2018;24:1779–1782. DOI: 10.1177/1352458518790391

Wijeyekoon RS, Kronenberg-Versteeg D, Scott KM, Hayat S, Jones JL, Clatworthy MR, Floto RA, Barker RA, Williams-Gray CH. Monocyte function in Parkinson’s disease and the impact of autologous serum on phagocytosis. Frontiers in Neurology. 2018;9:870. DOI: 10.3389/fneur.2018.00870

Pariani N, Willis M, Muller I, Helay S, Nasser T, McGowan A, Lyons G, Jones JL, Chatterjee K, Dayan C, Robertson N, Coles A, Moran C. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. Journal of Clinical Endocrinology & Metabolism. 2018;103:3010–3018. DOI: 10.1210/jc.2018-00359

Williams-Gray CH, Wijeyekoon RS, Scott KM, Hayat S, Barker RA, Jones JL. Abnormalities of age-related T cell senescence in Parkinson’s disease. Journal of Neuroinflammation. 2018;15:1–8. DOI: 10.1186/s12974-018-1206-5

Saarela M, Senthil K, Jones JL, Tienari PJ, Soilu-Hänninen M, Airas L, Coles A, Saarinen JT. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology. 2018;90:849–851. DOI: 10.1212/WNL.0000000000005420

Grist JT, Riemer F, McLean MA, Matys T, Zaccagna F, Hilborne SFM, Mason JP, Patterson I, Slough R, Kaggie J, Deen SS, Graves MJ, Jones JL, Coles AJ, Gallagher FA. Imaging intralesional heterogeneity of sodium concentration in multiple sclerosis: initial evidence from 23Na-MRI. Journal of the Neurological Sciences. 2018;387:111–114. DOI: 10.1016/j.jns.2018.01.027

Smets I, Fiddes B, Garcia-Perez JE, He D, Mallants K, Liao W, Dooley J, Wang G, Humblet-Baron S, Dubois B, Compston A, Jones JL, Coles A, Liston A, Ban M, Goris A, Sawcer S. Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. Brain. 2018;141:786–796. DOI: 10.1093/brain/awx372

Grist JT, Jarvis LB, Georgieva Z, Thompson S, Kaur Sandhu H, Burling K, Clarke A, Jackson S, Wills M, Gallagher FA, Jones JL. Extracellular lactate – a novel measure of T-cell proliferation. Journal of Immunology. 2018;200:1220–1226. DOI: 10.4049/jimmunol.1700886

Pekalski ML, García AR, Ferreira RC, Rainbow DB, Smyth DJ, Mashar M, Brady J, Savinykh N, Dopico XC, Mahmood S, Duley S, Stevens HE, Walker NM, Cutler AJ, Waldron-Lynch F, Dunger DB, Shannon-Lowe C, Coles AJ, Jones JL, Wallace C, Todd JA, Wicker LS. Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. JCI Insight. 2017;2:e93739. DOI: 10.1172/jci.insight.93739

Agarwal S, Patrick J, Jones J, Smith R, Coles A, Jayne D. Progressive multifocal leucoencephalopathy with Behçet’s disease: an insight into pathophysiology. Rheumatology. 2017:668–670. DOI: 10.1093/rheumatology/kew404

Davies JL, Thompson S, Kaur-Sandhu H, Sawcer S, Coles A, Ban M, Jones JL. Increased THEMIS first exon usage in CD4+ T-cells is associated with a genotype that is protective against multiple sclerosis. PLoS ONE. 2016;11:e0158327. DOI: 10.1371/journal.pone.0158327

Azzopardi L, Cox AL, McCarthy CL, Jones JL, Coles AJ. Alemtuzumab use in neuromyelitis optica spectrum disorders: a case series. Journal of Neurology. 2016;263:25–29. DOI: 10.1007/s00415-015-7925-y

Zandi MS, Paterson RW, Ellul MA, Jacobson L, Al-Diwani A, Jones JL, Cox AL, Lennox B, Stamelou M, Bhatia KP, Schott JM, Coles AJ, Kullmann DM, Vincent A. Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes. Journal of Neurology, Neurosurgery & Psychiatry. 2015;86:708–713. DOI: 10.1136/jnnp-2014-308736

Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, Robertson N, May K, Button T, Azzopardi L, Kousin-Ezewu O, Fahey MT, Jones JL, Compston DA, Coles A. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. Journal of Neurology, Neurosurgery & Psychiatry. 2015;86:208–215. DOI: 10.1136/jnnp-2014-307721

Jones JL, Coles AJ. Mode of action and clinical studies with alemtuzumab. Experimental Neurology. 2014;262:37–43. DOI: 10.1016/j.expneurol.2014.04.018

Azzopardi L, Thompson SA, Harding KE, Cossburn M, Robertson N, Compston A, Coles AJ, Jones JL. Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 2014;85:795–798. DOI: 10.1136/jnnp-2013-307042

Kousin-Ezewu O, Azzopardi L, Parker RA, Tuohy O, Compston A, Coles A, Jones JL. Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology. 2014;82:2158–2164. DOI: 10.1212/WNL.0000000000000520

Jones JL, Thompson SA, Loh P, Davies JL, Tuohy OC, Curry AJ, Azzopardi L, Hill-Cawthorne G, Fahey MT, Compston A, Coles AJ. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:20200–20205. DOI: 10.1073/pnas.1313654110

Brown JW, Coles AJ, Jones JL. First use of alemtuzumab in Balo’s concentric sclerosis: a case report. Multiple Sclerosis Journal. 2013;19:1673–1675. DOI: 10.1177/1352458513498129

McCarthy CL, Tuohy O, Compston DA, Kumararatne DS, Coles AJ, Jones JL. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013;81:872–876. DOI: 10.1212/WNL.0b013e3182a35215

Abrahamsson SV, Angelini DF, Dubinsky AN, Morel E, Oh U, Jones JL, Carassiti D, Reynolds R, Salvetti M, Calabresi PA, Coles AJ, Battistini L, Martin R, Burt RK, Muraro PA. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17-producing mucosal-associated invariant T cells in multiple sclerosis. Brain. 2013;136:2888–2903. DOI: 10.1093/brain/awt182

Hill-Cawthorne GA, Button T, Tuohy O, Jones JL, May K, Somerfield J, Green A, Giovannoni G, Compston DAS, Fahey MT, Coles AJ. Long-term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry. 2012;83:298–304. DOI: 10.1136/jnnp-2011-300826

Costelloe L, Jones JL, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Review of Neurotherapeutics. 2012;12:335–341. DOI: 10.1586/ern.12.5

Jones JL, Dean AF, Antoun N, Scoffings DJ, Burnet N, Coles AJ. Radiologically compatible CLIPPERS may conceal a number of pathologies. Brain. 2011;134:1–3. DOI: 10.1093/brain/awr134

Cossburn M, Pace AA, Jones JL, Ali R, Ingram G, Baker K, Hirst C, Zajicek J, Scolding N, Boggild M, Pickersgill T, Ben-Shlomo Y, Coles A, Robertson NP. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicentre cohort. Neurology. 2011;77:573–579. DOI: 10.1212/WNL.0b013e318228bec5

Jones JL, Anderson JM, Phuah C-L, Fox EJ, Selmaj K, Margolin D, Lake S, Wilkins A, Compston A, Coles AJ. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010;133:2232–2247. DOI: 10.1093/brain/awq176

Somerfield J, Hill-Cawthorne GA, Lin A, Zandi MS, McCarthy C, Jones JL, Wilcox M, Shaw D, Thompson SA, Compston AS, Hale G, Waldmann H, Coles AJ. A novel strategy to reduce the immunogenicity of biological therapies. Journal of Immunology. 2010;185:763–768. DOI: 10.4049/jimmunol.1000422

Jones JL, Coles AJ. New treatment strategies in multiple sclerosis. Experimental Neurology. 2010;225:34–39. DOI: 10.1016/j.expneurol.2010.06.003

Marsh EA, Hirst CL, Llewelyn JG, Cossburn MD, Reilly MM, Krishnan A, Doran M, Ryan AM, Coles AJ, Jones JL, Robertson NP. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. Journal of Neurology. 2010;257:913–919. DOI: 10.1007/s00415-009-5437-

Thompson SA, Jones JL, Cox AL, Compston DA, Coles AJ. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. Journal of Clinical Immunology. 2010;30:99–105. DOI: 10.1007/s10875-009-9327-3

Jones JL, Coles AJ. Spotlight on Alemtuzumab. International Journal of MS Care. 2009;16:77–81. PMID: 19878629

Jones JL, Phuah CL, Cox AL, Thompson SJ, Shawcross J, Ban M, Walton A, Sawcer SJ, Compston DAS, Coles AJ. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). Journal of Clinical Investigation. 2009;119:2052–2061. DOI: 10.1172/JCI37878

CAMMS223 Trial Investigators; Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. Alemtuzumab versus interferon beta-1a in early, relapsing-remitting multiple sclerosis. New England Journal of Medicine. 2008;359:1786–1801. DOI: 10.1056/NEJMoa0802670

Jones JL, Coles AJ. Campath-1H treatment of MS. Neurodegenerative Diseases. 2008;5:27–31. DOI: 10.1159/000109935

Coles AJ, Cox A, Le Page E, Jones JL, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy in relapsing-remitting and secondary progressive disease. Journal of Neurology. 2006;253:98–108. DOI: 10.1007/s00415-005-0934-5

Cox A, Thompson SA, Jones JL, Robertson VH, Hale G, Waldmann H, Compston DA, Coles AJ. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. European Journal of Immunology. 2005;35:3332–3342. DOI: 10.1002/eji.200535075

Pre-Prints

Guy Lam, Zhao Yang Xu, Adrien M Vaquié, Stavros Vagionitis, Michael Perry, Omar de Faria Jr, Georgios Solomou, John H Stockley, Gemma C Girdler, Daniel Yamamoto, Juan A Oses, Qianqian Zhang, Gregory Jordan, Laura R Morcom, Jacob Stillman, Hani Mousa, Alma Burlingame, Murray Stewart, Hauke B Werner, Andras Lakatos, Harry Bulstrode, Dorothy P Schafer, Joanne Jones, Ragnhildur T Karadottir, David H Rowitch. Myelin basic protein is an RNA chaperone in microglial nuclear retro-transport. bioRxiv May 2026. DOI: 10.64898/2026.05.14.725089. In submission to Nature Cell Biology.

Steven B Wells, Hamna Shahnawaz, Joanne L Jones. dreampy: Pseudobulk mixed-model differential expression for single-cell RNA-seq in Python. bioRxiv March 2026. DOI: 10.64898/2026.03.21.713408.

Talitha Forcier, Esther Cheng, Oliver H Tam, Cole Wunderlich, Laura Castilla-Vallmanya, Joanne L Jones, Annelies Quaegebeur, Roger A Barker, Johan Jakobsson, Molly Gale Hammell. TEsingle enables locus-specific transposable element expression analysis at single-cell resolution. bioRxiv March 2026. DOI: 10.64898/2026.03.19.712984.

Zoya Georgieva, Valerie Coppard, Jennie HM Yang, Richard Grenfell and Joanne L Jones. 34-parameter full spectrum immunophenotyping panel of human regulatory and effector lymphocytes. bioRxiv March 2024. DOI: 10.1101/2024.03.21.585958

Lorna B Jarvis, Sarah K Howlett, Valerie Coppard, Daniel Rainbow, Sarah Alkwai, Lou Ellis, Zoya Georgieva, Ondrej Suchanek, Hani Mousa, Krishnaa Mahbubani, Kourosh Saeb-Parsy, Linda S Wicker and Joanne L Jones. Hiding in Plain Sight: Thymic CD8+FOXP3+Tregs sequester CD25 and are enriched in human tissues. bioRxiv December 2023. DOI: 10.1101/2023.12.24.573232